An earlier study showed that LRRK2 inhibitor [i.e. GSK2578215A; GlaxoSmithKline (GSK)] attenuated abnormal lysosomal morphology and function in the PD patient fibroblasts and mouse primary cultures carrying LRRK2-G2019S variant63,64. This evidence concerns the gene LRRK2 and Parkinson disease.